PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020-PR Newswire APAC

PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020-PR Newswire APAC

DAEJEON, South Korea, Nov. 16, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) announced today that the company will present the final results of the Phase IIa clinical trial of Olinvacimab for rGBM (recurrent glioblastoma multiforme) patients at SNO (Society of Neuro-Oncology) 2020.

The clinical study was conducted in Australiafr...

Read more: PharmAbcine to present the final data of Phase IIa rGBM trial at SNO 2020-PR Newswire APAC

More Articles …

  1. Guardforce AI Bolsters its Services with Cybersecurity Offering and Robot as a Service Solution-PR Newswire APAC
  2. InfraRisk, Wagepay launch digital wage advance product to disrupt fintech market in Australia-PR Newswire APAC
  3. Arçelik Named Industry Leader in the Dow Jones Sustainability Index Once Again-PR Newswire APAC
  4. Gilead Sciences Announces Recipients of its First Asia HIV Research Scholar Program-PR Newswire APAC
  5. CommsChoice becomes Australia's first vendor of Contact Centre for Microsoft Teams Direct Routing-PR Newswire APAC
  6. Australian Crypto Exchange CEO Argues to Move All Long-Term Digital Asset Storage Offline-PR Newswire APAC
  7. PTC Therapeutics Announces Initiation of Phase 2/3 Clinical Trial in Australia to Evaluate PTC299 for the Treatment of COVID-19-PR Newswire APAC
  8. Lifestyle Hotel Brand TRYP by Wyndham Takes its Inaugural Trip to New Zealand-PR Newswire APAC
  9. The third CIIE concludes, $72.6 billion in intended deals for the coming year inked-PR Newswire APAC
  10. The fourth CIIE begins taking stall reservations from exhibitors-PR Newswire APAC